Results 51 to 60 of about 254,454 (341)

Is it safe for Multiple Sclerosis patients to fast? [PDF]

Journal of Fasting and Health, 2015
Ramadan fasting predispose multiple sclerosis (MS) patients to a great challenge. Clinicians should have practical knowledge about the effects of fasting on MS. A mini-symposium was held in 2013 to answer the common questions about fasting in MS patients.
Soodeh Razeghi Jahromi
doaj   +3 more sources

Brain atrophy at onset and physical disability in multiple sclerosis

Arquivos de Neuro-Psiquiatria, 2012
The aim of this study was to investigate if brain atrophy in multiple sclerosis (MS) patients during the disease onset predicts long term disability. METHODS: MS patients with follow-up time of at least 7 years from disease onset and with baseline and ...
Juan Ignacio Rojas, Liliana Patrucco, Cristina Besada, Laura Bengolea, Edgardo Cristiano   +4 more
doaj   +1 more source

Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups

Frontiers in Immunology, 2021
Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis (MS) are characterized by neurological deficits caused by a permanent neuronal damage, clinically quantified by the expanded disability status scale (EDSS). Neuronal tissue damage
Gloria Donninelli, Valeria Studer, Valeria Studer, Laura Brambilla, Chiara Zecca, Chiara Zecca, Daniele Peluso, Alice Laroni, Alice Laroni, Daniele Michelis, Renato Mantegazza, Paolo Confalonieri, Elisabetta Volpe   +12 more
doaj   +1 more source

Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy [PDF]

, 2017
The adult cerebral inflammatory form of X-linked adrenoleukodystrophy is a rapidly progressive neurodegenerative disease, as devastating as childhood cerebral adrenoleukodystrophy. Allogeneic haematopoietic stem cell transplantation has been demonstrated
Arnold, R., Aubourg, P., Gillett, G.T., Hemmati, P.G., Köhler, W., Kühl, J.S., Snowden, J.A., Stadler, M., Suarez, F., Vuong, G.L.   +9 more
core   +1 more source

Natural History of Early Onset Multiple Sclerosis

Pediatric Neurology Briefs, 2002
The clinical course of multiple sclerosis (MS) in 116 patients with onset before age 16 (prevalence 3.6% in total MS clinic attendees) was evaluated by longitudinal study (mean duration 19.76 +/- 0.9 years) at the University of British Columbia MS Clinic.
J Gordon Millichap
doaj   +1 more source

Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis [PDF]

, 2013
The Expanded Disability Status Scale (EDSS) is the current ‘gold standard’ for monitoring disease severity in multiple sclerosis (MS). The EDSS is a physician-based assessment.
Dobson, Ruth, Giovannoni, Gavin, Hadavi, Shahrzad, Leddy, Sara, McCarren, Andrew   +4 more
core   +1 more source

Factors influencing the degree of disability in patients with neuromyelitis optica spectrum disorders

European Journal of Medical Research, 2023
Objective To investigate the factors influencing the degree of disability in patients with neuromyelitis optica spectrum disorder (NMOSD) and provide evidence for disease monitoring and clinical intervention.
Lili Shi, Dawei Li, Yunxiu Zhang, Jinling Wang, Jingxuan Fu, Xia Liu, Peichang Wang   +6 more
doaj   +1 more source

Oligoclonal Band Status and Features of Radiological and Clinical Findings in Patients with Multiple Sclerosis in Lithuania

Medicina, 2023
Background and Objectives: Multiple sclerosis (MS) is a widely spread and debilitating disease with 2.8 million people worldwide currently affected.
Emilija Aleksandravičiūtė, Radvilė Stankevičiūtė, Renata Balnytė, Laurynas Šaknys, Ingrida Ulozienė   +4 more
doaj   +1 more source

Natural course of multiple sclerosis in the first five years of the disease in the Kujawsko-Pomorskie district

Aktualności Neurologiczne, 2016
Aim: The aim of the study was to emphasize the prognostic value of the first five years of the natural course of multiple sclerosis for the disability progression, and a comparison of the relapsing-remitting and the primary progressive disease course ...
Łukasz Rzepiński, Sławomir Wawrzyniak, Małgorzata Rzepińska   +2 more
doaj   +1 more source

Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021
Background Brain-derived neurotrophic factor (BDNF) is secreted by immune cells in response to neuroimmune and inflammatory cascades as an act to prevent axonal and neuronal damage after various pathological insults. The serum level of BDNF is altered in
Mohammed I. Oraby, Hatem A. El Masry, Sanaa S. Abd El Shafy, Esraa M. Abdul Galil   +3 more
doaj   +1 more source